Today, I no longer feel tied to a hospital bed and a grim diagnosis, and I have you to thank.
Site Search
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
Meet Hal Leshner, first-time hiker in the CF Foundation's Xtreme Hike, a fundraising event that challenges members of the CF community, and their families and friends, to take on the great outdoors.
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Meet a few faces from the 2015 Pittsburgh's 50 Finest event and learn how they raised funds and awareness for the CF cause.
This year our CF Foundation employee Great Strides team adopted a “Star Wars” theme and, believe me, we went all out to make the experience extra special and out of this world. See for yourself!
On April 7, the Foundation presented the Alex, Jena, and Dream Big Awards to leaders in the cystic fibrosis community for their dedication to the Foundation's mission of finding a cure.
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
I began volunteering as a way to support my cousin with CF. But over time, I discovered the community and impact that can come from even the smallest efforts.
To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.